Trial Profile
A Prospective, Open, Randomized, Controlled Clinical Study to Evaluate the Efficacy and Safety of PEG-rhG-CSF in Reducing Neutropenia in Patients With Cervical Cancer
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 02 Nov 2020
Price :
$35
*
At a glance
- Drugs Pegfilgrastim (Primary)
- Indications Neutropenia
- Focus Therapeutic Use
- 25 Aug 2017 Planned initiation date changed from 1 Jul 2017 to 1 Aug 2017.
- 04 Jul 2017 New trial record